# Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

> **NCT03639480** · PHASE3 · UNKNOWN · sponsor: **HK inno.N Corporation** · enrollment: 180 (estimated)

## Conditions studied

- Hypertension
- Hyperlipidemia

## Interventions

- **DRUG:** Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
- **DRUG:** Amlodipine 10mg+Valsartan 160mg
- **DRUG:** Valsartan 160mg+Atorvastatin 40mg

## Key facts

- **NCT ID:** NCT03639480
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-13
- **Primary completion:** 2018-10
- **Final completion:** 2018-10
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2018-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03639480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03639480, "Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03639480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*